BNTC at a glance
Benitec Biopharma Inc. (BNTC, SEC CIK 1808898) filed its latest 10-K annual report on September 14, 2026, a 10-Q quarterly report on May 14, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as June 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2024 (FY2024), Benitec Biopharma Inc. (BNTC) reported revenue of $0. Diluted EPS was -$5.51.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Benitec Biopharma Inc. (BNTC) shares worth $97.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by SUVRETTA CAPITAL MANAGEMENT, LLC on December 29, 2025 of 11,587 shares at $13.44 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2024
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $97.0M · +3 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 4.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Risk Factors
- Legislative risk: Medicare drug-price negotiation under Inflation Reduction Act of 2022 may limit pricing on reimbursed products
- Geopolitical risk: U.S. federal government workforce reductions cause FDA staffing shortages, potentially delaying product review and approvals
- Operational risk: Dependency on AAV delivery vectors may trigger immune responses restricting patient eligibility and efficacy of gene therapies
- Market disruption risk: Competition from antisense RNA therapies with more advanced development than ddRNAi-based products
- Financial risk: Accumulated losses $273.7M with cash runway estimated only for 12 months, requiring uncertain future capital raises
Business Overview
- Core business: Clinical-stage biotech developing permanent gene silencing and replacement therapies using proprietary ddRNAi platform
- New product focus: BB-301, first silence and replace AAV-based gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) in Phase 1b/2a clinical trial since Nov 2023
- Strategic emphasis on single-administration, durable gene therapy addressing limitations of RNAi, targeting rare disease with $1B+ commercial potential
- Employee count 24 as of June 30, 2026, with 17 R&D staff, reflecting small, specialized workforce
- Noteworthy patent advances include 2 new patent families in 2025-2026 covering interoperative delivery devices and modified AAV vectors for BB-301
Management Discussion & Analysis
- Revenue $0 for FY2026 and FY2025, no product sales generated
- Operating expenses $51.2M FY2026 vs $41.8M FY2025; R&D $23.4M vs $18.3M and G&A $27.8M vs $23.4M
- Best segment: none with revenue; highest expense: G&A $27.8M vs R&D $23.4M in FY2026
- Cash $180M as of June 30, 2026; net cash from financing $99.0M mostly from $104.5M stock issuance less $6.3M costs; operating cash outflow $16.5M
- Management outlook: increased R&D and G&A expenses expected; cash sufficiency projected for 12+ months; risks include development uncertainties and financing needs
AI summary of the BNTC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Risk Factors
- No risk factors provided in the submitted excerpt
- No new or changed risks identifiable from Items 2–6
- Regulatory disclosure limited to Sarbanes-Oxley certification exhibits
- No liquidity, debt, currency, concentration, operational, or competitive risks disclosed
AI summary of the BNTC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 4.01: Changes in Registrant's Certifying Accountant
- Ernst & Young LLP appointed independent registered public accounting firm for fiscal year ending June 30, 2027
- EY completed client acceptance procedures on September 28, 2026
Item 4.01: Changes in Registrant's Certifying Accountant
- Audit Committee appointed EY as independent auditor for fiscal year ending June 30, 2027
- EY engagement remains subject to completion of its client acceptance process
AI summaries of BNTC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BNTC
Don't miss the next BNTC filing
- Alerts as it files. A push when BNTC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BNTC, by share count.
- Ask anything. An AI agent that reads every BNTC filing and answers with sources.
BNTC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BUCHI J KEVIN | G | Jun 29, 2026 | 51,813 | - |
| Friedman David Matthew | A | May 26, 2026 | 35,000 | - |
| Mates Sharon | A | Jan 22, 2026 | 31,500 | - |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | Dec 29, 2025 | 11,587 | $13.44 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | Dec 29, 2025 | 65,800 | $13.44 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | Dec 26, 2025 | 2,516 | $13.10 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | Dec 26, 2025 | 14,320 | $13.10 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | Dec 23, 2025 | 7,400 | $12.85 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | $0 | - | - |
| Operating Income | -$22.5M | -$41.8M | -$51.2M |
| Net Income | - | -$37.9M | -$45.5M |
| Balance Sheet | |||
| Total Assets | $52.2M | $99.6M | $182.6M |
| Equity | - | $97.3M | $177.0M |
| ROE | - | -39.0% | -25.7% |
| Per Share | |||
| EPS | $-5.51 | $-1.05 | $-0.98 |
| Cash Flow | |||
| Operating CF | -$19.4M | -$23.6M | -$16.5M |
| CapEx | $179K | $18K | $105K |
Source: XBRL data in Benitec Biopharma Inc. (BNTC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BNTC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $97.0M |
| Q1 2026 | 20 | $70.9M |
| Q4 2025 | 17 | $50.5M |
| Q3 2025 | 15 | $74.4M |
| Q2 2025 | 14 | $57.3M |
| Q1 2025 | 9 | $44.2M |
| Q4 2024 | 5 | $42.0M |
| Q3 2024 | 4 | $8.6M |
- Millennium Management+269.2K (+41%)
- BlackRock+221.4K (+19%)
- State Street Corp+39.7K (+12%)
- Franklin Resources+34.7K (+1%)
- Vanguard Portfolio Management LLC+28.8K (+25%)
- Citadel Advisors LLC−90.3K (-53%)
- Goldman Sachs Group−37.4K (-17%)
- Morgan Stanley−9.7K (-33%)
- Ameriprise Financial−7.5K (-2%)
- Bank of America Corp−1.4K (-8%)
- AQR Capital Management+22.5K
- T. Rowe Price Group+18.5K
- Invesco Ltd+11.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 107 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BNTC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 10-K | Sep 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 10-Q | Feb 12, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 12, 2026 | - | - | |
| 4 | Jan 26, 2026 | - | - | |
| 4 | Dec 29, 2025 | - | - | |
| 4 | Dec 22, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| SC 13G | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 4 | Dec 3, 2025 | - | - | |
| 8-K | Dec 2, 2025 | - | - | |
| 10-Q | Nov 14, 2025 | Sep 30, 2025 | Analysis | |
| 10-K | Sep 22, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 14, 2025 | Mar 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BNTC SEC filings: frequently asked questions
Which institutions hold BNTC stock?
As of June 30, 2026, the largest Benitec Biopharma Inc. (BNTC) holders among the 13F filers tracked by SignalX were Franklin Resources ($32.3 million), BlackRock ($18.8 million), Vanguard Capital Management LLC ($12.8 million), Millennium Management ($12.3 million), Ameriprise Financial ($5.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BNTC's revenue in fiscal year 2024?
For the fiscal year ended June 30, 2024 (FY2024), Benitec Biopharma Inc. (BNTC) reported revenue of $0. Diluted EPS was -$5.51. The figures come from the XBRL data in the 10-K.
What are the main risks in BNTC's latest 10-K?
In the 10-K filed September 14, 2026, Benitec Biopharma Inc. (BNTC) flagged: Legislative risk: Medicare drug-price negotiation under Inflation Reduction Act of 2022 may limit pricing on reimbursed products. Geopolitical risk: U.S. federal government workforce reductions cause FDA staffing shortages, potentially delaying product review and approvals. (AI summary of the Risk Factors section.)
What did BNTC report in its latest 8-K?
Benitec Biopharma Inc. (BNTC) filed an 8-K on September 30, 2026 reporting Item 4.01 (Changes in Registrant's Certifying Accountant). Ernst & Young LLP appointed independent registered public accounting firm for fiscal year ending June 30, 2027.
What are the latest BNTC SEC filings?
Benitec Biopharma Inc. (BNTC) filed its latest 10-K annual report on September 14, 2026, a 10-Q quarterly report on May 14, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on June 30, 2026.
What is BNTC's SEC CIK number?
Benitec Biopharma Inc. (BNTC)'s SEC Central Index Key (CIK) is 1808898. EDGAR lists every BNTC filing under that number.
Ask anything about BNTC
The research agent reads BNTC's filings, financials, insider trades and 13F holders, then answers with sources.